Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Regulatory News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.10
Bid: 7.10
Ask: 7.48
Change: 0.29 (4.14%)
Spread: 0.38 (5.352%)
Open: 7.02
High: 7.10
Low: 7.00
Prev. Close: 7.00
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

23 Feb 2007 15:16

Synairgen plc23 February 2007 TR-1: NOTIFICATION OF MAJOR INTERESTS IN SHARES 1. Identity of the issuer or the underlying issuer of Synairgen plcexisting shares to which voting rights are attached: 2. Reason for the notification (please tick the appropriate box or boxes) An acquisition or disposal of voting rights ( ) An acquisition or disposal of financial instruments which may result in the ( )acquisition of shares already issued to which voting rights are attached An event changing the breakdown of voting rights ( ) Other (please specify): Confirmation of our Xholding___________________________________ 3. Full name of person(s) subject to the AMVESCAP plcnotification obligation: 4. Full name of shareholder(s) (if differentfrom 3.): 5. Date of the transaction (and date on whichthe threshold is crossed or reached ifdifferent): 6. Date on which issuer notified: 23 February 2007 7. Threshold(s) that is/are crossed or reached: 5%, 6% 8. Notified details: - A: Voting rights attached to sharesClass/type of Situation previous to the Resulting situation after the triggering transactionshares Triggering transaction if possible Number of Number of Number of Number of voting % of voting rightsusing the ISIN Shares Voting Rights shares rightsCODE Direct Direct Indirect Direct Indirect Ordinary 1p 1,314,211 1,314,211 1,314,211 1,314,211 6.05%Shares(GB00B0381Z20) B: Financial InstrumentsResulting situation after the triggering transactionType of financial Expiration date Exercise/ Conversion Number of voting rights % of votinginstrument Period/ Date that may be acquired if rights the instrument is exercised/ converted. - Total (A+B)Number of voting rights % of voting rights1,314,211 6.05% 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectivelyheld, if applicable: Chase Nominees - 743,836 Vidacos Nominees - 570,375 Proxy Voting: 10. Name of the proxy holder: 11. Number of voting rights proxy holder will cease to hold: 12. Date on which proxy holder will cease to hold votingrights: 13. Additional information: 14. Contact name: John Ward 15. Contact telephone number: 02380 512800 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
8th Dec 20117:00 amRNSEnd of Recruitment in Phase II Asthma Trial
25th Nov 20117:00 amRNSPositive Viral Pneumonia Study Results
10th Nov 201112:40 pmRNSResult of AGM
18th Oct 20111:50 pmRNSNotice of AGM and posting of Annual Reports
22nd Sep 20113:10 pmRNSGrant of options
9th Sep 20117:00 amRNSChange of Adviser
18th Jul 20117:00 amRNSJapanese Patent to be Granted
28th Jun 20117:00 amRNSPhase II asthma study - Interim Review and update
15th Jun 20113:56 pmRNSHolding(s) in Company
13th Jun 201111:54 amRNSResult of General Meeting
27th May 20111:00 pmRNSFundraising
4th May 20117:00 amRNSAntiviral activity against Bird Flu
2nd Feb 201111:31 amRNSHolding(s) in Company
1st Feb 20117:00 amRNSHalf Yearly Report
3rd Nov 20101:35 pmRNSResult of AGM
19th Oct 20107:00 amRNSUS Patent
8th Oct 20109:00 amRNSNotice of AGM and Posting of Annual Report
9th Sep 20107:00 amRNSGrant of Options
29th Jul 20107:00 amRNSFinal Results
27th Jul 20107:00 amRNSNotice of Results
29th Jun 20107:00 amRNSGrant of Options
28th Jun 20107:00 amRNSDirectorate Change
17th May 20107:00 amRNSPositive Influenza Data
6th May 20107:00 amRNSIFN-beta Patent Granted in Europe
1st Apr 20107:00 amRNSPhase II Trials
24th Feb 20103:27 pmRNSHolding(s) in Company
8th Feb 20107:00 amRNSHalf Yearly Report
15th Jan 20107:00 amRNSHolding(s) in Company
12th Nov 20097:00 amRNSSuccessful Outcome of Phase 1 Study
11th Nov 20091:24 pmRNSResult of AGM
9th Nov 20097:00 amRNSactivity of interferon beta against swine flu
26th Oct 20097:00 amRNSNotice of Investor Conference
14th Oct 20092:35 pmRNSNotice of Annual Report and Accounts and AGM
8th Sep 200911:25 amRNSGrant of Options
4th Sep 20097:00 amRNSDirectorate Changes
4th Sep 20097:00 amRNSUS Patent Granted
4th Sep 20097:00 amRNSFinal Results
2nd Sep 20097:00 amRNSNotice of Results
17th Jul 20093:00 pmRNSHolding(s) in Company
30th Jun 20099:56 amRNSTotal Voting Rights
25th Jun 20092:36 pmRNSHolding(s) in Company
23rd Jun 20097:00 amRNSHolding(s) in Company
15th Jun 200911:06 amRNSSecond Closing of the Fundraising
12th Jun 200911:22 amRNSResult of General Meeting
27th May 20097:00 amRNSFundraising Announcement
1st Apr 20097:00 amRNSPreliminary biomarker data
31st Mar 20097:00 amRNSChange of Adviser
26th Mar 20097:00 amRNSHalf Yearly Results
24th Mar 200911:14 amRNSNotice of Results
17th Mar 20097:00 amRNSProgress update: Clinical Trial - Interferon Beta

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.